Bausch + Lomb Co. (NYSE:BLCO) Shares Bought by Alberta Investment Management Corp

Alberta Investment Management Corp boosted its position in shares of Bausch + Lomb Co. (NYSE:BLCO) by 36.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,008,193 shares of the company’s stock after acquiring an additional 796,400 shares during the period. Alberta Investment Management Corp owned about 0.85% of Bausch + Lomb worth $54,328,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blue Trust Inc. grew its holdings in Bausch + Lomb by 68.3% during the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company’s stock worth $48,000 after acquiring an additional 1,004 shares in the last quarter. State Street Corp boosted its holdings in shares of Bausch + Lomb by 5.6% in the 3rd quarter. State Street Corp now owns 28,450 shares of the company’s stock valued at $549,000 after buying an additional 1,510 shares in the last quarter. HighTower Advisors LLC boosted its holdings in shares of Bausch + Lomb by 14.7% in the 3rd quarter. HighTower Advisors LLC now owns 24,661 shares of the company’s stock valued at $476,000 after buying an additional 3,164 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in shares of Bausch + Lomb in the 4th quarter valued at $72,000. Finally, Charles Schwab Investment Management Inc. raised its position in Bausch + Lomb by 80.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 29,755 shares of the company’s stock valued at $576,000 after purchasing an additional 13,302 shares during the last quarter. Institutional investors and hedge funds own 11.07% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. Morgan Stanley downgraded shares of Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 price target for the company. in a research report on Monday, December 2nd. Stifel Nicolaus reduced their price target on shares of Bausch + Lomb from $19.00 to $18.00 and set a “hold” rating for the company in a research report on Wednesday, January 29th. Needham & Company LLC restated a “hold” rating on shares of Bausch + Lomb in a research report on Thursday, October 31st. Royal Bank of Canada cut their price objective on shares of Bausch + Lomb from $23.00 to $22.00 and set an “outperform” rating for the company in a research report on Wednesday, January 29th. Finally, HC Wainwright restated a “buy” rating and set a $23.00 price objective on shares of Bausch + Lomb in a research report on Tuesday. One analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $20.25.

Bausch + Lomb Stock Performance

Shares of BLCO opened at $16.40 on Wednesday. The firm has a fifty day moving average of $17.51 and a 200-day moving average of $18.16. The company has a market cap of $5.78 billion, a price-to-earnings ratio of -15.61, a price-to-earnings-growth ratio of 2.13 and a beta of 0.46. Bausch + Lomb Co. has a 1 year low of $13.16 and a 1 year high of $21.69. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.